---
title: "Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295539574.md"
description: "New research has reinforced the efficacy of Cingulate's Precision Timed Release™ (PTR™) platform and its three-pronged drug delivery system. The study underscores the platform's effectiveness in delivering medication with precision timing. This validation adds to the growing body of evidence supporting PTR™, which has demonstrated remarkable outcomes in drug delivery. The findings highlight the platform's potential to enhance the targeted release of medications, offering a promising solution for optimized treatment."
datetime: "2026-08-11T12:33:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295539574.md)
  - [en](https://longbridge.com/en/news/295539574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295539574.md)
---

# Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

New research has reinforced the efficacy of Cingulate's Precision Timed Release™ (PTR™) platform and its three-pronged drug delivery system. The study underscores the platform's effectiveness in delivering medication with precision timing. This validation adds to the growing body of evidence supporting PTR™, which has demonstrated remarkable outcomes in drug delivery. The findings highlight the platform's potential to enhance the targeted release of medications, offering a promising solution for optimized treatment.

### Related Stocks

- [CING.US](https://longbridge.com/en/quote/CING.US.md)
- [CINGW.US](https://longbridge.com/en/quote/CINGW.US.md)

## Related News & Research

- [Cingulate publishes peer-reviewed pharmacokinetic study of ADHD candidate CTx-1301 in CNS Drugs](https://longbridge.com/en/news/295537403.md)
- [Cingulate Q2 FY26 net loss widens to $5.87 million; SG&A more than doubles to $3.93 million](https://longbridge.com/en/news/295798941.md)
- [Spyglass Pharma posts corporate deck on long-acting intraocular drug delivery for glaucoma, ocular hypertension patients](https://longbridge.com/en/news/295701214.md)
- [Pfizer just raised its 2026 guidance -- but the boost leans heavily on a drug running out the patent clock](https://longbridge.com/en/news/295581210.md)
- [Hims stock falls on earnings. Why a guidance hike isn’t enough.](https://longbridge.com/en/news/295453481.md)